HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 90.0%

Neg 90% Neu 0% Pos 0%

HC Wainwright & Co. analyst Robert Burns downgrades ADC Therapeutics (NYSE:ADCT) from Buy to Neutral.

Comments

No comments yet. Be the first!